文献速递间质性肺疾病

奥米帕利西(PI3K/mTOR抑制剂)治疗特发性肺纤维化的随机安慰剂对照研究

A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis.
PubMed 文献 · Eur Respir J · 2019-03-18

该随机、安慰剂对照、双盲、重复剂量递增实验医学研究在17例特发性肺纤维化(IPF)受试者中评估奥米帕利西(GSK2126458)的安全性、耐受性、药代动力学和药效学。奥米帕利西以0.25 mg、1 mg和2 mg每日两次给药8天,最常见不良事件为腹泻(4例),观察到胰岛素和葡萄糖剂量相关升高,药效学显示靶点结合及肺纤维化区域18F-FDG摄取暴露依赖性降低。研究表明在确认系统性和肺部靶点结合的暴露水平下,奥米帕利西耐受性可接受。

要点

  • 奥米帕利西在IPF受试者中耐受性可接受,最常见不良事件为腹泻。
  • 观察到胰岛素和葡萄糖剂量相关升高。
  • 确认系统性和肺部靶点结合,肺纤维化区域18F-FDG摄取暴露依赖性降低。

核心结论

  • 奥米帕利西在IPF受试者中耐受性可接受,暴露水平确认了系统性和肺部靶点结合。

研究设计与样本

  • 随机、安慰剂对照、双盲、重复剂量递增实验医学研究(NCT01725139)。
  • 17例IPF受试者入组,四个队列每组4例按3:1随机接受奥米帕利西或安慰剂(两个队列接受2 mg每日两次)。
  • 奥米帕利西剂量为0.25 mg、1 mg和2 mg每日两次,给药8天。

主要发现

  • 最常见不良事件为腹泻,4例参与者报告。
  • 观察到胰岛素和葡萄糖剂量相关升高。
  • 药代动力学分析表明血液暴露可预测肺部暴露。
  • 暴露依赖性抑制磷脂酰肌醇3,4,5三磷酸和pAKT,确认血液和肺部靶点结合。
  • 18F-FDG PET/CT显示肺纤维化区域18F-FDG摄取暴露依赖性降低(以靶/本底比值衡量)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) play a role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is a potent inhibitor of PI3K/mTOR.A randomised, placebo-controlled, double-blind, repeat dose escalation, experimental medicine study of omipalisib in subjects with IPF was conducted (NCT01725139) to test safety, tolerability, pharmacokinetics and pharmacodynamics. Omipalisib was dosed at 0.25 mg, 1 mg and 2 mg twice daily for 8 days in four cohorts of four subjects randomised 3:1 to receive omipalisib or placebo (two cohorts received 2 mg twice daily).17 subjects with IPF were enrolled. The most common adverse event was diarrhoea, which was reported by four participants. Dose-related increases in insulin and glucose were observed. Pharmacokinetic analysis demonstrated that exposure in the blood predicts lung exposure. Exposure-dependent inhibition of phosphatidylinositol 3,4,5 trisphosphate and pAKT confirmed target engagement in blood and lungs. 18F-2-fluoro-2-deoxy-d-glucose(FDG)-positron emission tomography/computed tomography scans revealed an exposure-dependent reduction in 18F-FDG uptake in fibrotic areas of the lung, as measured by target-to-background, ratio thus confirming pharmacodynamic activity.This experimental medicine study demonstrates acceptable tolerability of omipalisib in subjects with IPF at exposures for which target engagement was confirmed both systemically and in the lungs.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Lukey PT, Harrison SA, Yang S, et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur Respir J. 2019. PMID: 30765508. doi:10.1183/13993003.01992-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。